Literature DB >> 29968553

Case Report: Orbital Tumor Revealing Adult T-Cell Leukemia/Lymphoma Associated with Human T-Cell Lymphotropic Virus Type-1.

Selim Farès1, Rabih Hage1, Jean Pegliasco2, Samy Chraibi2, Harold Merle1.   

Abstract

Adult T-cell Leukemia/Lymphoma (ATLL) is a sight- and life-threatening complication of human T-cell lymphotropic virus type 1 (HTLV-1) infection. Ophthalmic manifestations include uveitis, optic nerve oedema, retinal vasculitis, and lymphomatous infiltration. Orbital lesions are rare. We report the case of an orbital tumor revealing systemic ATLL in a 45-year-old Dominican patient who died despite treatment. Apart from late-grade cutaneous T-cell lymphoma, ATLL is the only T-lymphoma to develop in the orbit. Diagnosis is based on serologic evidence of HTLV-1 infection, cytology, and blood sample analysis. Biopsy is deemed necessary. Given the poor prognosis of ATLL and the worldwide presentation of HTLV-1, physicians should consider ATLL in the differential diagnosis of orbital malignant tumor and look for HTLV-1 infection in populations at risk.

Entities:  

Mesh:

Year:  2018        PMID: 29968553      PMCID: PMC6090341          DOI: 10.4269/ajtmh.17-0137

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  28 in total

Review 1.  Current views in HTLV-I-associated adult T-cell leukemia/lymphoma.

Authors:  Christophe Nicot
Journal:  Am J Hematol       Date:  2005-03       Impact factor: 10.047

2.  Orbital mass secondary to precursor T-cell acute lymphoblastic leukemia: a rare presentation.

Authors:  B Esmaeli; L J Medeiros; J Myers; R Champlin; S Singh; L Ginsberg
Journal:  Arch Ophthalmol       Date:  2001-03

3.  Long-term maintenance combination chemotherapy with OPEC/MPEC (vincristine or methotrexate, prednisolone, etoposide and cyclophosphamide) or with daily oral etoposide and prednisolone can improve survival and quality of life in adult T-cell leukemia/lymphoma.

Authors:  K Matsushita; T Matsumoto; H Ohtsubo; H Fujiwara; N Imamura; S Hidaka; T Kukita; C Tei; M Matsumoto; N Arima
Journal:  Leuk Lymphoma       Date:  1999-12

4.  RETINAL MANIFESTATIONS IN ADULT T-CELL LEUKEMIA/LYMPHOMA RELATED TO INFECTION BY THE HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE-1.

Authors:  Harold Merle; Rabih Hage; Jean-Côme Meniane; Christophe Deligny; Yves Plumelle; Angélique Donnio; Albert Jean-Charles
Journal:  Retina       Date:  2016-07       Impact factor: 4.256

5.  Ocular manifestations in patients infected with human T-lymphotropic virus type I.

Authors:  N Ohba; M Matsumoto; M Sameshima; Y Kabayama; K Nakao; K Unoki; F Uehara; K Kawano; I Maruyama; M Osame
Journal:  Jpn J Ophthalmol       Date:  1989       Impact factor: 2.447

6.  Immunologic markers, uveitis, and keratoconjunctivitis sicca associated with human T-cell lymphotropic virus type 1.

Authors:  Sônia Regina A A Pinheiro; Olindo A Martins-Filho; João Gabriel R Ribas; Bernadette C Catalan-Soares; Fernando A Proietti; Sueli Namen-Lopes; Gustavo E A Brito-Melo; Anna Baŕbara F Carneiro-Proietti
Journal:  Am J Ophthalmol       Date:  2006-09-20       Impact factor: 5.258

7.  Ocular manifestations of adult T-cell leukemia/lymphoma. A clinicopathologic study.

Authors:  T Kohno; H Uchida; H Inomata; S Fukushima; M Takeshita; M Kikuchi
Journal:  Ophthalmology       Date:  1993-12       Impact factor: 12.079

8.  Survey of 1264 patients with orbital tumors and simulating lesions: The 2002 Montgomery Lecture, part 1.

Authors:  Jerry A Shields; Carol L Shields; Richard Scartozzi
Journal:  Ophthalmology       Date:  2004-05       Impact factor: 12.079

9.  Successfully treated optic nerve infiltration with adult T-cell lymphoma.

Authors:  N Yamamoto; M Kiyosawa; T Kawasaki; T Miki; T Fujino; T Tokoro
Journal:  J Neuroophthalmol       Date:  1994-06       Impact factor: 3.042

10.  Epidemiological Aspects and World Distribution of HTLV-1 Infection.

Authors:  Antoine Gessain; Olivier Cassar
Journal:  Front Microbiol       Date:  2012-11-15       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.